FR3119987B1 - Hydrogel composition and uses thereof in the prevention and/or treatment of radiation damage to the skin - Google Patents

Hydrogel composition and uses thereof in the prevention and/or treatment of radiation damage to the skin Download PDF

Info

Publication number
FR3119987B1
FR3119987B1 FR2101620A FR2101620A FR3119987B1 FR 3119987 B1 FR3119987 B1 FR 3119987B1 FR 2101620 A FR2101620 A FR 2101620A FR 2101620 A FR2101620 A FR 2101620A FR 3119987 B1 FR3119987 B1 FR 3119987B1
Authority
FR
France
Prior art keywords
treatment
prevention
skin
hydrogel composition
radiation damage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2101620A
Other languages
French (fr)
Other versions
FR3119987A1 (en
Inventor
Gareth Winckle
Philippe Andres
Janusz Czernielewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tarian Pharma SAS
Original Assignee
Tarian Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR2101620A priority Critical patent/FR3119987B1/en
Application filed by Tarian Pharma SAS filed Critical Tarian Pharma SAS
Priority to JP2023550646A priority patent/JP2024507266A/en
Priority to US18/264,286 priority patent/US20240100044A1/en
Priority to EP22706811.1A priority patent/EP4294370A1/en
Priority to CN202280015187.5A priority patent/CN116887813A/en
Priority to KR1020237031798A priority patent/KR20230147668A/en
Priority to AU2022224394A priority patent/AU2022224394A1/en
Priority to PCT/EP2022/054037 priority patent/WO2022175428A1/en
Priority to CA3204652A priority patent/CA3204652A1/en
Publication of FR3119987A1 publication Critical patent/FR3119987A1/en
Application granted granted Critical
Publication of FR3119987B1 publication Critical patent/FR3119987B1/en
Priority to ZA2023/06750A priority patent/ZA202306750B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L’invention concerne une composition sous une forme adaptée à une administration par voie topique à base d’eau comprenant un vasoconstricteur. L’invention se caractérise en ce que la composition comprend un vasoconstricteur choisi parmi la brimonidine ou ses sels, dans une phase solvantée comprenant : - du polyéthylène glycol en combinaison avec du propylène glycol et/ou du diméthylsulfoxyde (DMSO) ; - un copolymère Polyvinylpyrrolidone/Vinyl Acetate comme agent filmogène hydrophile ; - de la glycérine ; et en ce qu’elle se présente sous forme d’hydrogel. L’invention concerne également la composition selon l’invention pour son utilisation en tant que médicament, plus particulièrement dans la prévention et/ou le traitement de dermatite résultant d’un rayonnement notamment dans le cadre d’un traitement par radiothérapie. Figure 9The invention relates to a composition in a form suitable for topical water-based administration comprising a vasoconstrictor. The invention is characterized in that the composition comprises a vasoconstrictor chosen from brimonidine or its salts, in a solvent phase comprising: - polyethylene glycol in combination with propylene glycol and/or dimethyl sulphoxide (DMSO); - a Polyvinylpyrrolidone/Vinyl Acetate copolymer as a hydrophilic film-forming agent; - glycerin; and in that it is in the form of a hydrogel. The invention also relates to the composition according to the invention for its use as a medicament, more particularly in the prevention and/or treatment of dermatitis resulting from radiation, in particular in the context of radiotherapy treatment. Picture 9

FR2101620A 2021-02-19 2021-02-19 Hydrogel composition and uses thereof in the prevention and/or treatment of radiation damage to the skin Active FR3119987B1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR2101620A FR3119987B1 (en) 2021-02-19 2021-02-19 Hydrogel composition and uses thereof in the prevention and/or treatment of radiation damage to the skin
CA3204652A CA3204652A1 (en) 2021-02-19 2022-02-18 Hydrogel composition and uses thereof in the prevention and/or treatment of skin damage caused by radiation
EP22706811.1A EP4294370A1 (en) 2021-02-19 2022-02-18 Hydrogel composition and uses thereof in the prevention and/or treatment of skin damage caused by radiation
CN202280015187.5A CN116887813A (en) 2021-02-19 2022-02-18 Hydrogel composition and its use in preventing and/or treating skin injury caused by radiation
KR1020237031798A KR20230147668A (en) 2021-02-19 2022-02-18 Hydrogel composition and use thereof in preventing and/or treating skin damage caused by radiation
AU2022224394A AU2022224394A1 (en) 2021-02-19 2022-02-18 Hydrogel composition and uses thereof in the prevention and/or treatment of skin damage caused by radiation
JP2023550646A JP2024507266A (en) 2021-02-19 2022-02-18 Hydrogel compositions and their use in the prevention and/or treatment of radiation-induced skin damage
US18/264,286 US20240100044A1 (en) 2021-02-19 2022-02-18 Hydrogel composition and uses thereof in the prevention and/or treatment of skin damage caused by radiation
PCT/EP2022/054037 WO2022175428A1 (en) 2021-02-19 2022-02-18 Hydrogel composition and uses thereof in the prevention and/or treatment of skin damage caused by radiation
ZA2023/06750A ZA202306750B (en) 2021-02-19 2023-06-30 Hydrogel composition and uses thereof in the prevention and/or treatment of skin damage caused by radiation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2101620 2021-02-19
FR2101620A FR3119987B1 (en) 2021-02-19 2021-02-19 Hydrogel composition and uses thereof in the prevention and/or treatment of radiation damage to the skin

Publications (2)

Publication Number Publication Date
FR3119987A1 FR3119987A1 (en) 2022-08-26
FR3119987B1 true FR3119987B1 (en) 2023-01-13

Family

ID=75278238

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2101620A Active FR3119987B1 (en) 2021-02-19 2021-02-19 Hydrogel composition and uses thereof in the prevention and/or treatment of radiation damage to the skin

Country Status (10)

Country Link
US (1) US20240100044A1 (en)
EP (1) EP4294370A1 (en)
JP (1) JP2024507266A (en)
KR (1) KR20230147668A (en)
CN (1) CN116887813A (en)
AU (1) AU2022224394A1 (en)
CA (1) CA3204652A1 (en)
FR (1) FR3119987B1 (en)
WO (1) WO2022175428A1 (en)
ZA (1) ZA202306750B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4306112A1 (en) * 2022-07-15 2024-01-17 Tarian Pharma New dosage regimen of a composition containing brimonidine for use in the prevention and treatment of skin damage resulting from radiation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150119401A1 (en) * 2008-08-01 2015-04-30 Eye Therapies, Llc Compositions and Methods for the Treatment of Nasal Conditions
CA3061196A1 (en) * 2017-05-26 2018-11-29 Scott Whitcup A topical composition for treating rosacea and a method for treating rosacea with the same

Also Published As

Publication number Publication date
FR3119987A1 (en) 2022-08-26
AU2022224394A1 (en) 2023-09-21
EP4294370A1 (en) 2023-12-27
CA3204652A1 (en) 2022-08-25
JP2024507266A (en) 2024-02-16
CN116887813A (en) 2023-10-13
KR20230147668A (en) 2023-10-23
ZA202306750B (en) 2024-02-28
WO2022175428A1 (en) 2022-08-25
US20240100044A1 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
US10426787B2 (en) Topical compositions and methods for treating psoriasis
AU2006339842B2 (en) Pharmaceutical composition for external use
US20220008555A1 (en) Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
US20200046739A1 (en) Pharmaceutical tetracycline composition for dermatological use
AU2013323766B2 (en) Topical ketoprofen composition
EP2364692A3 (en) Compositions including at least one derivative of naphtoic acid, benzoyl peroxide and at least one film-forming agent, methods for preparing same and uses thereof
EA200601724A1 (en) NEW COMPOSITIONS FOR LOCAL DELIVERY
CN111904926B (en) Topical diclofenac sodium compositions
US8636988B2 (en) Composition for treatment of sunburned skin
US20190091333A1 (en) Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
MA20150062A1 (en) Semi-solid topical composition containing pirfenidone and modified dialyl disulfide oxide (odd-m) to eliminate or prevent acne
FR3119987B1 (en) Hydrogel composition and uses thereof in the prevention and/or treatment of radiation damage to the skin
FR3119986B1 (en) Water-in-oil emulsion composition and its uses in the prevention and/or treatment of skin damage caused by radiation
JP2008531640A (en) Antifungal composition comprising sertaconazole and hydrocortisone and / or antibacterial quinolone compound
EP0996442B1 (en) Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative
AR069831A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLADDER CANCER
AU2004262934B2 (en) Topical composition comprising terbinafine and hydrocortisone
JP2018520110A (en) Ophthalmic composition comprising lipoic acid and mucosal mimetic polymer
JPH0231052B2 (en)
WO2007138233A2 (en) Use of zatosetron for the treatment of rosacea, and pharmaceutical compositions
EP3329910B1 (en) Pharmaceutical composition for preventing or treating onychomycosis and preparation method therefor
US20240016762A1 (en) Dual analgesic/anti-inflammatory compositions comprising cb2 receptor agonists, combinations, and methods of use thereof
JP2008150344A (en) Semi-solid external preparation for antipruritic use
JP5999875B2 (en) Gel-like pharmaceutical composition
EP1874291B1 (en) Use of zinc gluconate for treating hydradenitis suppurativa

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20220826

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4